Daily Penny Stock Gainers: IVOB, LTSN, MDCE
Stocks recently turned lower after failing to extend their opening climb. Financials and tech issues had been a source of leadership, but strength in the two sectors has been checked in recent trade.
The stock market’s slip comes even though the euro has continued to climb against the greenback. The euro is now up 1.3% to $1.305, which makes for its best level in nearly three weeks.
IVOB – Trade Alert
Up 55.94% in morning trading to $.0499 with 1M shares traded
INVO Bioscience is a medical device company, headquartered in Beverly, Massachusetts, focused on creating simplified, lower cost treatment options for patients diagnosed with infertility. The company’s lead product, the INVOcell, is a novel medical device used in infertility treatment that enables egg fertilization and early embryo development in the woman’s vaginal cavity. The company was founded by Claude Ranoux, MD, a noted expert in the field of reproductive health, infertility and embryology. INVO Bioscience, Inc. (OTC BB: IVOB) Friday announced that the National Health Surveillance Agency (ANVISA) in Brazil has granted approval of the INVOcell for use as a Class II device.
To Read Full Story go to: http://www.pennytrader.com/
********************
LTSN - News Alert
Up 27.27% in morning trading to $.70 with 800K shares traded
LTS Nutraceuticals, Inc. develops, manufactures, markets and distributes an expanding line of unique, high-quality vitamins, vitamin boosters, dietary supplements and nutraceuticals. The products are sold throughout North America through two marketing channels: direct selling utilizing Inline Marketing™ to introduce products to the consumer and marketing products through national retail, drug and grocery chains and club stores. LTS Nutraceuticals, Inc. (OTCBB: LTSN) today announced that a clinical study was done on BioCalth® product that confirmed BioCalth’s effectiveness in repairing bone deterioration. The study was conducted by Dr. Jing Liang MD PhD, Associate Professor of Molecular & Medical Pharmacology at the David Geffen School of Medicine, UCLA. Dr. Liang has over 20 years of experience in pharmaceutical research and development.
To Read Full Story go to: http://www.pennytrader.com/
********************
MDCE - News Alert
Up 64.71% in morning trading to $.0028 with 6M shares traded
Medical Care Technologies Inc., through joint ventures or Chinese subsidiaries, develops a network of children’s health facilities in the larger urban areas throughout China. Services are geared towards the advancing economic middle-class and upper class Chinese families. Medical Care Technologies Inc. (OTCBB: MDCE) announced that it has closed a $130,000 loan agreement with a private Hong Kong company. Proceeds will go towards license completion and construction to operate its first children’s health and wellness center located in Dongguan, Guangdong Province, China.
To Read Full Story go to: http://www.pennytrader.com/
********************
To Follow PennyTrader on Twitter: http://twitter.com/pennytrader
To Join Our Facebook Page: http://www.facebook.com/PennyTrader2
PennyTrader.com, PO Box 791, Prosper, TX 75078, Telephone: (972) 546-3740, Email: Publisher@PennyTrader.com.This email address is being protected from spam bots, you need Javascript enabled to view it
DO NOT BASE ANY INVESTMENT DECISION UPON ANY MATERIALS FOUND ON THIS REPORT. We are not registered as a securities broker-dealer or an investment adviser either with the U.S. Securities and Exchange Commission (the “SEC”) or with any state securities regulatory authority. We are neither licensed nor qualified to provide investment advice. PennyTrader.com makes no recommendation that the purchase of securities of companies profiled in this web site is suitable or advisable for any person or that an investment such securities will be profitable. In general, given the nature of the companies profiled and the lack of an active trading market for their securities, investing in such securities is highly speculative and carries a high degree of risk. You are receiving this email because you have registered on PennyTrader.com or one of our affiliate companies.
The information contained in our report should be viewed as commercial advertisement and is not intended to be investment advice. The report is not provided to any particular individual with a view toward their individual circumstances. The information contained in our report is not an offer to buy or sell securities. We distribute opinions, comments and information free of charge exclusively to individuals who wish to receive them.
Our newsletter and website have been prepared for informational purposes only and are not intended to be used as a complete source of information on any particular company. An individual should never invest in the securities of any company profiled based solely on information contained in our reports. Individuals should assume that all information contained in the report about profiled companies is not trustworthy unless verified by their own independent research.
Any individual who chooses to invest in any securities should do so with caution. Investing in securities is speculative and carries a high degree of risk; you may lose some or all of the money that is invested. Always research your own investments and consult with a registered investment advisor or licensed stock broker before investing.
Information contained in our report will contain “forward looking statements” as defined under Section 27A of the Securities Act of 1933 and Section 21B of the Securities Exchange Act of 1934. Subscribers are cautioned not to place undue reliance upon these forward looking statements. These forward looking statements are subject to a number of known and unknown risks and uncertainties outside of our control that could cause actual operations or results to differ materially from those anticipated. Factors that could affect performance include, but are not limited to, those factors that are discussed in each profiled company’s most recent reports or registration statements filed with the SEC. You should consider these factors in evaluating the forward looking statements included in the report and not place undue reliance upon such statements. We are committed to providing factual information on the companies that are profiled. However, we do not provide any assurance as to the accuracy or completeness of the information provided, including information regarding a profiled company’s plans or ability to effect any planned or proposed actions. We have no first-hand knowledge of any profiled company’s operations and therefore cannot comment on their capabilities, intent, resources, nor experience and we make no attempt to do so. Statistical information, dollar amounts, and market size data was provided by the subject company and related public information sources which we believe to be reliable but we cannot guarantee the accuracy of the information. To the fullest extent of the law, we will not be liable to any person or entity for the quality, accuracy, completeness, reliability, or timeliness of the information provided in the report, or for any direct, indirect, consequential, incidental, special or punitive damages that may arise out of the use of information we provide to any person or entity (including, but not limited to, lost profits, loss of opportunities, trading losses, and damages that may result from any inaccuracy or incompleteness of this information). We encourage you to invest carefully and read investment information available at the websites of the SEC at http://www.sec.gov and FINRA at http://www.finra.org.
Disclosure: PennyTrader.com is not currently being compensated for any stocks covered in this midday report.
Leave a Comment